Briefing · From the Watchtower
CancerNetwork: CHMP backed Lifyorli combo for platinum-resistant ovarian cancer
CancerNetwork and Corcept's wire release via STT Info report the glucocorticoid-receptor antagonist combo cleared the EMA's CHMP on 18 September 2026; the binding European Commission decision follows, which the company expects in the fourth quarter of 2026.
Oncology trade outlets (OncLive, CancerNetwork), together with Corcept's own wire release republished via MarketScreener and STT Info, reported on 18 September 2026 that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for Corcept Therapeutics' Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer [1][2][3][4]. The opinion is a committee recommendation, not a final authorization: the binding European Commission decision follows, which Corcept expects in the fourth quarter of 2026 [4].
Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist [10][11]. The combination is already FDA-approved, cleared in March 2026 as Lifyorli (NDA 220641) for adults who have had one to three prior systemic regimens including at least one containing bevacizumab [6][7][8]. That prior-bevacizumab requirement places the drug after, not against, the anti-angiogenic standard — it extends the treatment sequence rather than displacing its front end.
Why it matters
The US launch is already moving: Corcept reported more than 1,300 US patients started on Lifyorli since the March 2026 approval, and $47.6 million in product revenue in Q2 2026 [8]. An EU authorization would open a second major market for a drug whose commercial case is being proven in real time. For any competitor building in platinum-resistant ovarian cancer, this is a second geography coming into play, not a distant possibility.
The pivotal Phase 3 (NCT05257408), a dual PFS/OS study that is active but no longer recruiting, with a primary completion date of 24 March 2025, has no results posted in its public registry record [14].
What we could not verify
The European Commission's final decision is the binding step, and Corcept expects it in the fourth quarter of 2026 [4]; that is a company expectation, not a confirmed authorization date.
What to watch next
Corcept expects results from its triple combination of relacorilant, nab-paclitaxel and bevacizumab (NCT06906341, still recruiting) by the end of 2026 [12][15]; a positive readout there would push relacorilant into concurrent use with the anti-angiogenic rather than strictly after it.
The now-what
For a competitor in platinum-resistant ovarian cancer, the planning priorities are concrete. Prognyx’s planning implication: scenario-test a potential EU launch after the Commission decision; neither an authorization nor a launch date is confirmed by the company’s fourth-quarter decision expectation [4]. Watch the end-2026 triple-combination readout — it decides whether relacorilant stays a later-line option or moves earlier in the sequence. And because glucocorticoid receptor antagonism is mechanistically independent of PARP inhibition and anti-angiogenics, the sharper question is whether it combines with those classes rather than competes with them.
Verdict: moderate and rising threat for platinum-resistant ovarian franchises — the EU door is opening, and the window to respond runs until the Commission decision (company expects the fourth quarter of 2026 [4]) and the end-2026 triple-combination data.
Questions this briefing answers
Is Lifyorli now approved in the European Union?
No. On 18 September 2026 the EMA's CHMP issued a positive opinion recommending EU marketing authorization; the binding European Commission decision still follows, which Corcept expects in the fourth quarter of 2026 [2][4].
How is relacorilant different from existing platinum-resistant ovarian cancer drugs?
It is a non-steroidal, selective glucocorticoid receptor antagonist given with nab-paclitaxel — a mechanism distinct from the anti-angiogenics used in the platinum-resistant setting and the PARP inhibitors used elsewhere in ovarian cancer. Its US label places it after at least one prior bevacizumab-containing regimen [6][10][11].
Sources — every claim traces to the primary record
- OncLive — CHMP recommends relacorilant + nab-paclitaxel for PROC
- CancerNetwork — relacorilant combo positive CHMP opinion in ovarian cancer
- MarketScreener (wire republication) — Corcept receives CHMP recommendation
- STT Info (press release wire) — Corcept announces CHMP opinion for Lifyorli
- FDA label (DailyMed) — Lifyorli prescribing information
- Drugs@FDA — LIFYORLI (COPACKAGED), NDA 220641
- SEC 8-K (Corcept, EX-99.1, 29 July 2026) — Q2 2026 results
- SEC 8-K (Corcept, EX-99.1, 17 June 2026) — mechanism & orphan designations
- ChEMBL — relacorilant (CHEMBL4068611), GR antagonist, max phase 3
- ClinicalTrials.gov NCT06906341 — relacorilant combos in gynecological cancers
- ClinicalTrials.gov NCT05257408 — Phase 3 relacorilant + nab-paclitaxel (dual PFS/OS)
- SEC 8-K (Corcept, EX-99.1, 29 July 2026) — triple-combination results expected end 2026
How this briefing was produced — Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.
The Watchtower, by email
Each briefing, the day it publishes.
One email per briefing, nothing else. You confirm by clicking the link we send; you leave in one click.
Double opt-in. Never sold, no open tracking. Privacy.
Get a free sample competitive brief on one of your assets — sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.